Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and Radiation Therapy in Colorectal and Pancreatic Cancer
NCT03104439Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2017
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in colorectal cancer (CRC) and pancreatic cancer (PC), sponsored by Massachusetts General Hospital. Primary endpoint: Disease Control Rate at 2 years. Started May 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03104439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104439.